High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 127; pp. 37 - 43
• Main Authors: Hsu, Kuo-Hsuan, Huang, Yen-Hsiang, Tseng, Jeng-Sen, Chen, Kun-Chieh, Ku, Wen-Hui, Su, Kang-Yi, Chen, Jeremy J.W., Chen, Huei-Wen, Yu, Sung-Liang, Yang, Tsung-Ying, Chang, Gee-Chen
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.01.2019
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Aged; Antineoplastic Agents - therapeutic use; Drug Resistance, Neoplasm; Epidermal growth factor receptor mutation; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Mutation - genetics; Neoplasm Staging; Primary resistance; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - metabolism; Programmed cell death-ligand 1; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Adenocarcinoma; Epidermal growth factor receptor mutation; Primary resistance; Lung cancer; Programmed cell death-ligand 1

•The level of PD-L1 expression can predict efficacy of EGFR-TKI.•Higher PD-L1 expression had high incidence of primary resistance to EGFR TKI.•Higher PD-L1 expression had shorter progression-free survival. The main objective was to investigate the relationship between Programmed cell Death-ligand 1...